Prognostic factors in patients with pleural mesothelioma: The European organization for research and treatment of cancer experience

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 145-152

  Curran, Desmond ^a   Sahmoud, Tarek ^a   Therasse, Patrick ^a   van Meerbeeck, Jan ^a   Postmus, Pieter E ^a   Giaccone, Giuseppe ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; ETOPOSIDE; MITOXANTRONE; PACLITAXEL;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; SARCOMA; SCORING SYSTEM; SEX DIFFERENCE;

EID: 0031961891     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.145     Document Type: Article

References (57)

1. Alberts AS, Falkson G, Goedhals L, et al: Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 6:527-535, 1988
2. Legha SS, Muggia FM: Pleural mesothelioma: Clinical features and therapeutic implications. Ann Intern Med 87:613-621, 1977
3. De Klerk NH, Armstrong BK: The epidemiology of asbestos and mesothelioma, in Henderson DW, Shelkin KB, Langlois SLP, et al (eds): Malignant Mesothelioma. New York, NY, Hemisphere, 1992, pp 223-243
4. Wagner JC, Sleggs CA, Marchand P: Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape province. Br J Ind Med 17:260-271, 1960
5. Antman KH: Current concepts: Malignant mesothelioma. N Engl J Med 303:200-202, 1980
6. Ashcrott T: Epidemiological and quantitative relationships between mesothelioma and asbestos on Tyneside. J Clin Pathol 26:832, 1973
7. Nicholson WJ, Perkel G, Selikoff IJ: Occupational exposure to asbestos: Population at risk and projected mortality: 1980-2030. Am J Indust Med 3:259-311, 1982
8. Mossman BT, Gee JBL: Asbestos-related diseases. N Engl J Med 320:1721-1730, 1989
9. Chahinian AP, Pajak TF, Holland JF: Diffuse malignant mesothelioma. Ann Intern Med 96:746-755, 1982
10. Ruffle P, Feld R, Minkin S, et al: Diffuse malignant mesothelioma of the pleura in Ontario and Quebec; A retrospective study of 322 patients. J Clin Oncol 7:1157-1168, 1989
11. De Pangher Manzini V, Brollo A, et al: Prognostic factors of malignant mesothelioma of the pleura. Cancer 72:410-417, 1993
12. Boutin C, Rey F, Gouvernet J, et al: Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Cancer 72:394-404, 1993
13. Chailleux E, Dabuois G, Pioche D, et al: Prognostic factors in diffuse malignant pleural mesothelioma. Chest 93:159-162, 1988
14. Samson MK, Wasser LP, Borden EC, et al: Randomized comparison of cyclophosphamide, imidazole carboxamide, and Adriamycin versus Adriamycin in patients with advanced stage malignant mesothelioma: A Sarcoma Intergroup study. J Clin Oncol 5:86-91, 1987
15. Antman KH, Shemin R, Ryan L, et al: Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1968. J Clin Oncol 6:147-153, 1988
16. Calavrezos A, Koschel G, Hüsselmann H, et al: Malignant mesothelioma of the pleura. Klin Wochenschr 66:607-613, 1988
17. Schildge J, Kaiser D, Henss H, et al: Prognostische Faktoren beim diffusen malignen Mesothelioma der Pleura. Pneumologie 43:660-664, 1989
18. Chahinian AP, Antman K, Goutsou M, et al: Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 11:1559-1565, 1993
19. Tammilehto L: Malignant mesothelioma: Prognostic factors in a prospective study of 98 patients. Lung Cancer 8:175-184, 1992
20. Pepper C, Jasani B, Navabi H, et al: Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue. Thorax 51:1074-1076, 1996
21. Strickler HD, Goedert JJ, Fleming M, et al: Simian virus 40 and pleural mesothelioma in humans. Cancer Epidemiol Biomarkers Prev 5:473-475, 1996
22. Spirtas R, Connelly RR, Tucker MA: Survival patterns for malignant mesothelioma: The SEER experience. Int J Cancer 41:525-530, 1988
23. Simon R, Altman DG: Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69:979-985, 1994
24. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-202, 1972
25. Harrell FE, Lee KL, Matchar DB, et al: Regression models for prognostic prediction: Advantages, problems and suggested solutions. Cancer Treat Rep 69:1071-1077, 1985
26. van Breukelen FJM, Mattson K, Giaccone G, et al: Mitoxantrone in malignant pleural mesothelioma: A study by the EORTC Lung Cooperative Group. Eur J Cancer 27:1627-1629, 1991
27. Mattson K, Giaccone G, Kirkpatrick A, et al: Epirubicin in malignant mesothelioma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 10:824-828, 1992
28. Sahmoud T, Postmus P, van Pottelsberghe C, et al: Etoposide in malignant pleural mesothelioma: Phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (in press)
29. van Meerbeeck J, Debruyne C, van Zandwijk N, et al: Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 74:961-963, 1996
30. Van Gelder T, Hoogsteden HC, Vandenbroucke JP, et al: The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma. Virchows Arch A 418:315-317, 1991
31. Braunwald, Fauci, Haujer et al (eds): Harrison's Principles of Internal Medicine (ed 14). New York, NY, McGraw-Hill, 1997
32. Breslow N: Comparison of survival curves, in Buyse ME, Staquet MJ, Sylvester RJ (eds): Cancer Clinical Trials, Methods and Practice. Oxford, United Kingdom, Oxford Medical, 1988, pp 382-406
33. Cox DR, Oakes D: Analysis of Survival Data. London, United Kingdom, Chapman & Hall, 1984
34. Rao CR: Linear Statistical Inference and Its Applications. New York, NY, Wiley, 1973
35. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
36. SAS Technical Report: The PHREG Procedure. Cary, NC, SAS Institute, 1991, p 217
37. Rusch VW, Piantadosi S, Holmes EC: The role of extrapleural pneumonectomy in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 102:1-9, 1991
38. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991
39. Graham MV, Geitz LM, Byhardt R, et al: Comparison of prognostic factors and survival among black patients and white patients treated with irradiation for non-small cell lung cancer. J Natl Cancer Inst 84:1731-1735, 1992
40. Shinkai T, Eguchi K, Sasaki Y, et al: A prognostic factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 30:1-6, 1992
41. Ries LA: Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol 10:21-30, 1994
42. Engan T, Hannisdal E: Blood analyses as prognostic factors in primary lung cancer. Acta Oncol 29:151-154, 1990
43. Hernandez E, Heller PB, Whitney C, et al: Thrombocytosis in surgically treated stage IB squamous cell cervical carcinoma (a Gynecologic Oncology Group study). Gynecol Oncol 55:328-332, 1994
44. Hernandez E, Lavine M, Dunton CJ, et al: Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 69:2975-2977, 1992
45. Lopez A, Daras V, Cross PA, et al: Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer 74:90-92, 1994
46. Rodriguez GC, Clarke-Pearson DL, Soper JT, et al: The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. Obstet Gynecol 83:445-448, 1994
47. Gastl G, Plante M, Finstad CL, et al: High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 83:433-441, 1993
48. Higashihara M, Sunaga S, Tange T, et al: Increased secretion of interleukin-6 in malignant mesothelioma cells for a patient with marked thrombocytosis. Cancer 70:2105-2108, 1992
49. Shimoda K, Okamura S, Harada N, et al: Production of interleukin-6 from macrophages by MDP-Lys (L 18), romurtide. Res Commun Chem Pathol Pharmacol 70:289-296, 1990
50. Fitzpatrick DR, Peroni DJ, Bielefeidt-Ohmann H: The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 12:455-460, 1995
51. Sakamoto A, Katakami H, Mukae H, et al: Simultaneous production of parathyroid hormone-related protein (PTHrP) and granulocyte colony-stimulating factor (G-CSF) in lung cancer patients with hypercalcemia and leukocytosis. Nippon Kyobu Shikkan Gakkai Zasshi 33:34-38, 1995
52. Adachi N, Yamaguchi K, Morikawa T, et al: Constitutive production of multiple colony-stimulating factors in patients with lung cancer associated with neutrophilia. Br J Cancer 69:125-129, 1994
53. Aisner J: Current approach to malignant mesothelioma of the pleura. Chest 107:332S-344S, 1995
54. Sugarbaker DJ, Strauss GM, Lynch TJ, et al: Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11:1172-1178, 1993
55. Keller SM: Adjuvant therapy for malignant pleural mesothelioma. Chest Surg Clin N Am 4:127-135, 1994
56. Sugarbaker DJ, Garcia JP, Richards WG, et al: Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 224:288-294, 1996
57. Schiebe M, Hoffmann W, Kortmann RD, et al: The clinical picture and therapy of malignant pleural mesothelioma. Strahlenther Onkol 170:628-635, 1994